STOCK TITAN
  1. Home
  2. Sec-filings
  3. TMCI
  4. [Form 4] TREACE MEDICAL CONCEPTS, INC. Insider Trading Activity

Treace Medical Concepts (TMCI) director receives 30,000 RSU equity award

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Kiernan Jane E reported acquisition or exercise transactions in this Form 4 filing.

Treace Medical Concepts director Jane E. Kiernan received a new equity award in the form of restricted stock units (RSUs). The Form 4 shows a grant of 30,000 RSUs with no cash paid per unit, bringing her direct holdings to 93,949 shares of common stock, including these RSUs.

The RSUs will be 100% vested on the earlier of May 19, 2027 or the date of the 2027 annual stockholder meeting, as long as she continues serving the company through that date. She has also elected to defer delivery of the underlying shares until the earlier of a change in control of the company or her separation of service, so the grant is a long-term, service-based compensation award rather than an immediate share issuance.

Positive

  • None.

Negative

  • None.
Insider Kiernan Jane E
Role null
Type Security Shares Price Value
Grant/Award Common Stock 30,000 $0.00 --
Holdings After Transaction: Common Stock — 93,949 shares (Direct, null)
Footnotes (1)
  1. Represents restricted stock units (RSUs) for which the Reporting Person is entitled to receive one (1) share of Issuer's Common Stock for each RSU upon vesting. The RSUs will be 100% vested on the earlier of (a) May 19, 2027 or (b) the date of the 2027 annual meeting of stockholders, subject to Reporting Person's providing continued service to Issuer through the vesting date. The Reporting Person voluntarily elected to defer receipt of the shares of the Issuer's Common Stock issuable upon settlement of the RSUs until the earlier of a change in control or the Reporting Person's separation of service to the Issuer. Includes 30,000 restricted stock units.
RSU grant size 30,000 RSUs Restricted stock units granted to director on May 19, 2026
Grant price $0.00 per unit RSU award issued as compensation, not purchased in market
Post-grant holdings 93,949 shares Total common stock holdings after transaction, including 30,000 RSUs
RSU vesting date May 19, 2027 100% vesting on this date or 2027 annual meeting, whichever is earlier
restricted stock units (RSUs) financial
"Represents restricted stock units (RSUs) for which the Reporting Person is entitled to receive one (1) share..."
Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.
change in control financial
"until the earlier of a change in control or the Reporting Person's separation of service..."
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
separation of service financial
"until the earlier of a change in control or the Reporting Person's separation of service to the Issuer."
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Kiernan Jane E
(Last)(First)(Middle)
C/O TREACE MEDICAL CONCEPTS, INC.
100 PALMETTO PARK PLACE
(Street)
PONTE VEDRA FLORIDA 32081
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
TREACE MEDICAL CONCEPTS, INC. [ TMCI ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/19/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/19/2026A30,000(1)A$093,949(2)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents restricted stock units (RSUs) for which the Reporting Person is entitled to receive one (1) share of Issuer's Common Stock for each RSU upon vesting. The RSUs will be 100% vested on the earlier of (a) May 19, 2027 or (b) the date of the 2027 annual meeting of stockholders, subject to Reporting Person's providing continued service to Issuer through the vesting date. The Reporting Person voluntarily elected to defer receipt of the shares of the Issuer's Common Stock issuable upon settlement of the RSUs until the earlier of a change in control or the Reporting Person's separation of service to the Issuer.
2. Includes 30,000 restricted stock units.
/s/ Lisa Taylor as Attorney-in-fact for Jane E. Kiernan05/19/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Treace Medical Concepts (TMCI) director Jane E. Kiernan report on this Form 4?

Jane E. Kiernan reported receiving a grant of 30,000 restricted stock units (RSUs). These RSUs represent a form of stock-based compensation and will convert into shares of Treace Medical Concepts common stock upon future vesting and settlement, rather than an immediate open-market purchase.

How many shares does Jane E. Kiernan hold after this Treace Medical Concepts (TMCI) RSU grant?

After the RSU grant, Jane E. Kiernan is shown holding 93,949 shares of Treace Medical Concepts common stock. This figure includes the 30,000 restricted stock units reported in the filing, reflecting her total direct equity position reported as of the transaction date.

When do Jane E. Kiernan’s 30,000 Treace Medical Concepts (TMCI) RSUs vest?

The 30,000 RSUs vest 100% on the earlier of May 19, 2027 or the date of Treace Medical Concepts’ 2027 annual stockholder meeting. Vesting is conditioned on Kiernan continuing to provide service to the company through the applicable vesting date.

Did Jane E. Kiernan buy Treace Medical Concepts (TMCI) shares on the open market in this Form 4?

No, this Form 4 reports a grant of restricted stock units at a price of $0.00 per unit. It reflects a compensation-related acquisition rather than an open-market purchase or sale of Treace Medical Concepts common stock by the director.

How will the Treace Medical Concepts (TMCI) RSUs reported by Jane E. Kiernan be settled?

Each RSU entitles Jane E. Kiernan to receive one share of Treace Medical Concepts common stock upon vesting. She elected to defer receipt of the shares until the earlier of a change in control of the company or her separation of service from Treace.

What conditions affect Jane E. Kiernan’s Treace Medical Concepts (TMCI) RSU award?

The RSUs require continued service to Treace Medical Concepts through vesting, which occurs in 2027 based on time or the annual meeting date. Additionally, she has chosen to defer settlement until either a change in control or her separation of service from the company.